The implications of Blackstone’s property wobble by Viewsroom

  • 📰 Breakingviews
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

🔊 Blackstone’s market value slumped after it said investors were exiting its flagship real estate fund. JMAGuilford and johnsfoley join TheRealLSL to discuss the causes of the jitters and how rivals are vulnerable to similar moves. Listen 👉

Breakingviews columnists talk about the big numbers, crunchy deals and nasty spats in global business and economics, .

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 470. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Breakingviews - The complexities of EY’s big breakup bet: podcastThe Big Four firm is pushing a plan to separate its auditing unit from its consulting business. In this Exchange podcast Andy Baldwin, global managing partner, discusses the challenges of convincing partners in over 70 countries to back the split – and what happens if it fails.
Source: Breakingviews - 🏆 470. / 51 Read more »

Breakingviews - Vietnam’s Tesla faces daunting Nasdaq road testElectric-car maker VinFast’s U.S. initial public offering will be a tough drive. The company, which filed its listing prospectus on Tuesday, has yet to turn a profit and only just went all-in on battery power. Its dependency on parent Vingroup may be a turnoff, too. Investors will kick the tires hard.
Source: Breakingviews - 🏆 470. / 51 Read more »

Breakingviews - Big Pharma’s heartburn win is a valuation salvePharmaceutical investors are accustomed to disappointment. An industry rule of thumb says that nine out of 10 drugs fail clinical trials, while treatments that succeed can bite companies on the tail if they have unanticipated side effects. The ghost of massive legal bill that drugmaker Bayer paid in 2020 has been haunting the sector. But a U.S. judge just made that spectre seem less threatening. Breakingviews aimeedonnellan I bet big pharma would be more careful about drugs they introduce if every time someone dies from one of their meds, one of them died as well. Breakingviews aimeedonnellan Reuters advocates for big Pharma and the clot shots.
Source: Breakingviews - 🏆 470. / 51 Read more »